مباشر

Endpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year Endpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and more FierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs Endpoints News#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetes Clinical OMICsBlood-Based Risk Score Could Enable Earlier Lung Cancer Prevention Clinical OMICsMicroglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to Dementia Endpoints NewsIn Washington, biotech's China hawks are winning the conversation Clinical OMICsUniversal Coronavirus Vaccine Could Provide Protection Against Future Strains Endpoints NewsIndustry seeks more clarity on commissioner's voucher program BioWorldMoney raised by biopharma BioWorldBiopharma money raised: Jan. 1-June 4, 2026 BioWorldBioWorld and Nasdaq stock indices

FierceBiotech ٦ يونيو ٢٠٢٦

‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs

When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show p...

When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clinic.